![Caroline Stout](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Caroline Stout
Direttore degli Investimenti presso PANACEA ACQUISITION CORP. II
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Oleg Nodelman | M | 47 |
EcoR1 Capital, LLC
![]() EcoR1 Capital, LLC Investment ManagersFinance EcoR1 Capital LLC (EcoR1) is an independent registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Oleg Nodelman in 2012. EcoR1 serves as the general partner of and investment adviser to investment funds and provides investment advice to separate account clients. | 12 anni |
Carsten Linnemann | M | - |
Neogene Therapeutics, Inc.
![]() Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | 6 anni |
David Tanen | M | 52 |
Neogene Therapeutics, Inc.
![]() Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | 6 anni |
Sarah Marriott | F | 46 | 3 anni | |
Nina Kjellson | F | 49 | 3 anni | |
Basheer Zada | M | - |
EcoR1 Capital, LLC
![]() EcoR1 Capital, LLC Investment ManagersFinance EcoR1 Capital LLC (EcoR1) is an independent registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Oleg Nodelman in 2012. EcoR1 serves as the general partner of and investment adviser to investment funds and provides investment advice to separate account clients.
Georgetown University
| 8 anni |
Charles Sigal | M | 72 |
Affinia Therapeutics, Inc.
![]() Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 anni |
Scott Platshon | M | 32 |
EcoR1 Capital, LLC
![]() EcoR1 Capital, LLC Investment ManagersFinance EcoR1 Capital LLC (EcoR1) is an independent registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Oleg Nodelman in 2012. EcoR1 serves as the general partner of and investment adviser to investment funds and provides investment advice to separate account clients. | 9 anni |
Ton Schumacher | M | - |
Neogene Therapeutics, Inc.
![]() Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | 6 anni |
Rick Modi | M | 55 |
Affinia Therapeutics, Inc.
![]() Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 anni |
Carole Faig | F | 62 |
Affinia Therapeutics, Inc.
![]() Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 anni |
Praveen Tipirneni | M | 55 | 3 anni | |
Douglas Williams | M | 66 | 3 anni | |
Dave Grayzel | M | 56 |
Affinia Therapeutics, Inc.
![]() Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 anni |
Ed Mathers Mathers | M | 64 |
Affinia Therapeutics, Inc.
![]() Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 anni |
Sean Nolan | M | 56 |
Affinia Therapeutics, Inc.
![]() Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 anni |
Douglas Giordano | M | 61 | 3 anni | |
Luk Vandenberghe | M | 47 |
Affinia Therapeutics, Inc.
![]() Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 anni |
Aaron Tward | M | - |
Affinia Therapeutics, Inc.
![]() Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 anni |
Laura Richman | M | 60 |
Affinia Therapeutics, Inc.
![]() Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 anni |
Mike Bush | M | - |
Georgetown University
| 13 anni |
Rajul Jain | M | - |
Neogene Therapeutics, Inc.
![]() Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | - |
Petra Kaufmann | M | 58 |
Affinia Therapeutics, Inc.
![]() Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 anni |
Rob Aboud | M | 59 |
Affinia Therapeutics, Inc.
![]() Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 anni |
Raul Jain | M | - |
Neogene Therapeutics, Inc.
![]() Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | - |
Rachel Mears | F | - |
Neogene Therapeutics, Inc.
![]() Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | 4 anni |
Brent Pfeiffenberger | M | 46 |
Neogene Therapeutics, Inc.
![]() Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | 3 anni |
Scott Perlen | M | 48 | 3 anni | |
Sarah Spencer | F | - |
EcoR1 Capital, LLC
![]() EcoR1 Capital, LLC Investment ManagersFinance EcoR1 Capital LLC (EcoR1) is an independent registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Oleg Nodelman in 2012. EcoR1 serves as the general partner of and investment adviser to investment funds and provides investment advice to separate account clients. | 6 anni |
Diana Brainard | M | 53 |
Affinia Therapeutics, Inc.
![]() Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 2 anni |
Charles Albright | M | 66 |
Affinia Therapeutics, Inc.
![]() Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 anni |
Katherine Wood | F | 38 |
Neogene Therapeutics, Inc.
![]() Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | 4 anni |
Ira Shoulson | M | 77 |
Georgetown University
| 13 anni |
Botond Roska | M | 54 |
Affinia Therapeutics, Inc.
![]() Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 anni |
Alexander Tkachenko | M | - |
EcoR1 Capital, LLC
![]() EcoR1 Capital, LLC Investment ManagersFinance EcoR1 Capital LLC (EcoR1) is an independent registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Oleg Nodelman in 2012. EcoR1 serves as the general partner of and investment adviser to investment funds and provides investment advice to separate account clients. | - |
Martin Murphy | M | 55 |
Neogene Therapeutics, Inc.
![]() Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | - |
Joe Amato | M | 62 |
Georgetown University
| 11 anni |
Robert May | M | 56 |
Affinia Therapeutics, Inc.
![]() Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
M. William Benedetto | M | 83 |
Georgetown University
| - |
Fernando Bunker Gentil | M | 74 |
Georgetown University
| 8 anni |
Max Cascante | M | - |
Georgetown University
| 5 anni |
Joseph Sum | M | - |
EcoR1 Capital, LLC
![]() EcoR1 Capital, LLC Investment ManagersFinance EcoR1 Capital LLC (EcoR1) is an independent registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Oleg Nodelman in 2012. EcoR1 serves as the general partner of and investment adviser to investment funds and provides investment advice to separate account clients. | - |
Robert Forsythe | M | - |
Georgetown University
| 4 anni |
Carolina Delgado | F | - |
Georgetown University
| 4 anni |
Lee Keller | F | - |
Georgetown University
| 4 anni |
Jack Smith | M | - |
Georgetown University
| 4 anni |
Erin Cannata | F | 34 |
Georgetown University
| 4 anni |
Lindsay Finan | F | - |
Georgetown University
| 4 anni |
Thomas Schwartz | M | - |
Georgetown University
| 1 anni |
Holly Jacobus | F | - |
Georgetown University
| 3 anni |
Charlie Hough | M | - |
Georgetown University
| 4 anni |
Max Mickiewicz | M | - |
Georgetown University
| 4 anni |
Hunter M. Kelly | M | - |
Georgetown University
| 4 anni |
Kevin Formica | M | - |
Georgetown University
| 4 anni |
Jacopo Meneguzzo | M | - |
Georgetown University
| 4 anni |
Todd Reese | M | - |
Georgetown University
| 4 anni |
Maxwell Mortimer | M | - |
Georgetown University
| 4 anni |
Jose Arredondo | M | - |
Georgetown University
| 4 anni |
Michael Li | M | - |
Georgetown University
| 3 anni |
Ryan Mahon | M | - |
Georgetown University
| 4 anni |
Catherine Henry | F | - |
Georgetown University
| 4 anni |
Alejandra Calvo Boullosa | F | - |
Georgetown University
| 4 anni |
Lu Ying Wang | F | - |
Georgetown University
| 4 anni |
Bohbot Samantha | F | - |
Georgetown University
| 3 anni |
David Dietz | M | - |
Georgetown University
| 4 anni |
Emily Durfee | F | - |
Georgetown University
| 4 anni |
David Weis | M | - |
Georgetown University
| 4 anni |
Graham Robertson | M | - |
Georgetown University
| 4 anni |
David Nulsen | M | - |
Georgetown University
| 2 anni |
Barrett Veazey | M | - |
Georgetown University
| 4 anni |
Alessia Maria Apostolatos | F | - |
Georgetown University
| 4 anni |
Alicia Che | F | - |
Georgetown University
| 4 anni |
James Myrtetus | M | - |
Georgetown University
| 4 anni |
Ryan Dodge | M | - |
Georgetown University
| 4 anni |
Kevin Nishimura | M | - |
Georgetown University
| - |
Jeffrey Emerson Bailin | M | - |
Georgetown University
| 4 anni |
Michael T. Roberts | M | - |
Georgetown University
| 3 anni |
Gary M. Shiffman | M | - |
Georgetown University
| 10 anni |
Gonçalo João Figueira Morais Soares | M | 53 |
Georgetown University
| 2 anni |
Hugh B. McBride | M | - |
Georgetown University
| 4 anni |
David Corak | M | - |
Georgetown University
| 4 anni |
David Young | M | - |
Georgetown University
| 13 anni |
Donald McLee | M | - |
Georgetown University
| 4 anni |
Mark Charles Greenfield | M | - |
Georgetown University
| 4 anni |
Arjun Mehta | M | - |
Georgetown University
| 4 anni |
Matthew Joseph McDonough | M | - |
Georgetown University
| 4 anni |
Joe McIlhattan | M | - |
Georgetown University
| 4 anni |
Matthew Joseph Simpson | M | - |
Georgetown University
| 4 anni |
Marshall Coltrain | M | - |
Georgetown University
| 4 anni |
Keir Renick | M | - |
Georgetown University
| 2 anni |
Glenn M. Russo | M | - |
Georgetown University
| 4 anni |
Aaron Keller | M | - |
Georgetown University
| 3 anni |
Sean Viscount | M | - |
Georgetown University
| 4 anni |
MaryAnne L. Zhao | F | - |
Georgetown University
| 4 anni |
Stephen West | M | - |
Georgetown University
| 3 anni |
Edward Lee | M | - |
Georgetown University
| 4 anni |
Shaked Atia | F | - |
Georgetown University
| 4 anni |
Kevin Ma | M | - |
Georgetown University
| 4 anni |
Robert Ackerman | M | - |
Georgetown University
| 2 anni |
Greg Warren | M | - |
Georgetown University
| 3 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Caroline Stout
- Contatti personali